Literature DB >> 8093729

Chronic spinal infusion of dexmedetomidine, ST-91 and clonidine: spinal alpha 2 adrenoceptor subtypes and intrinsic activity.

Y Takano1, T L Yaksh.   

Abstract

The antinociceptive effect (hot plate test) and behavioral changes produced by the continuous 7-day i.t. infusion of alpha 2 adrenoceptor agonists dexmedetomidine (10 and 3 nmol/hr), clonidine (100 and 30 nmol/hr) and 2-(2,6-diethylphenylamino)-2-imidazoline (ST-91) (30 and 10 nmol/hr) were examined in rats. The highest doses of each agonist produced an equivalent increase in hot plate latency on day 1 of infusion. These effects diminished to near base line by 5 to 7 days. In separate groups, i.t. dose-response curves were obtained with dexmedetomidine, clonidine and ST-91 in groups of rats which had received a 7-day infusion of saline or the equianalgesic concentrations of dexmedetomidine (10 nmol/hr) or ST-91 (30 nmol/hr). Dose-response curves in drug-infused animals showed a right shift as compared to the vehicle-infused rats. Calculation of the ratio of the ED50 values (tolerance ratio: drug vs. control) in animals receiving the continuous infusion of dexmedetomidine vs. saline indicated: 8- (6-12), 36- (19-54) and 1.0- (0.6-1.5) (ratio with 95% Cl) fold rightward shifts of dexmedetomidine, clonidine and ST-91 dose-response curves, respectively. Chronic infusion of ST-91 resulted in 62- (36-127), 22- (13-46) and 0.9- (0.7-1.1) fold rightward shift of the ST-91, clonidine and dexmedetomidine dose-response curves, respectively. Previously, we have shown that dexmedetomidine and clonidine act upon spinal alpha 2 adrenoceptor, which appeared distinguishable from that acted upon by ST-91.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093729

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  [Epidural and intrathecal administration of alpha 2-adreno-ceptor agonists for postoperative pain relief].

Authors:  M G Rockemann; W Seeling
Journal:  Schmerz       Date:  1996-04-25       Impact factor: 1.107

2.  Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.

Authors:  Saikat Chakraborty; Vincent Elvezio; Martin Kaczocha; Mario Rebecchi; Michelino Puopolo
Journal:  J Physiol       Date:  2017-02-22       Impact factor: 5.182

3.  Dexmedetomidine blocks thermal hyperalgesia and spinal glial activation in rat model of monoarthritis.

Authors:  Bo Xu; Wei-shi Zhang; Jia-le Yang; Hua Xu; Xiao-ming Deng; Yu-qiu Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-04-05       Impact factor: 6.150

4.  Effects of spinal naloxone and naltrindole on the antinociceptive action of intrathecally administered dexmedetomidine.

Authors:  Y Takano; M Takano; I Sato; T L Yaksh
Journal:  J Anesth       Date:  1996-09       Impact factor: 2.078

5.  Clonidine and dexmedetomidine produce antinociceptive synergy in mouse spinal cord.

Authors:  Carolyn A Fairbanks; Kelley F Kitto; H Oanh Nguyen; Laura S Stone; George L Wilcox
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

6.  [Antinociceptive effects of alpha(2)-adrenoceptor agonists ("analgesic" actions in animal experiments)agonists ("analgesic" actions in animal experiments).].

Authors:  I Jurna
Journal:  Schmerz       Date:  1995-11       Impact factor: 1.107

7.  Development of tolerance to antinociceptive effects of an intrathecal morphine/clonidine combination in rats.

Authors:  J L Plummer; P L Cmielewski; S Tallents; P D Hall; J Odontiadis; G K Gourlay; H Owen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.